Remove Documentation Remove Pharmaceutical Manufacturing Remove Specialty Pharmacies
article thumbnail

NOW AVAILABLE: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

article thumbnail

NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

reviews the evolving specialty pharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities. and Section 6.4.3. A new Section 6.2.2.

article thumbnail

Formularies, Formulary Strategies, and Vigilante Formulary Review

Ramblings of a pharmacist

We can also see from this excerpt that at the scale of large PBMs, formulary strategies are also a piece of negotiating leverage to obtain rebates and fees from pharmaceutical manufacturers. However, once negotiations are completed and rebate contracted executed, rebates can be cut off punitively by pharmaceutical manufacturers.